Financials data is unavailable for this security.
View more
Year on year Alkem Laboratories Ltd grew revenues 9.21% from 115.99bn to 126.68bn while net income improved 82.47% from 9.84bn to 17.96bn.
Gross margin | 63.10% |
---|---|
Net profit margin | 17.01% |
Operating margin | 17.02% |
Return on assets | 13.49% |
---|---|
Return on equity | 19.89% |
Return on investment | 18.66% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Alkem Laboratories Ltd fell by 2.07bn. However, the company earned 19.48bn from its operations for a Cash Flow Margin of 15.38%. In addition the company used 10.09bn on investing activities and also paid 11.45bn in financing cash flows.
Cash flow per share | 206.87 |
---|---|
Price/Cash flow per share | 27.09 |
Book value per share | 961.22 |
---|---|
Tangible book value per share | 916.28 |
More ▼
Balance sheet in INRView more
Current ratio | 2.66 |
---|---|
Quick ratio | 1.97 |
Total debt/total equity | 0.1286 |
---|---|
Total debt/total capital | 0.1104 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 60.00% and 82.47%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 0.91% |
---|---|
Div growth rate (5 year) | 20.11% |
Payout ratio (TTM) | 2.82% |
EPS growth(5 years) | 18.75 |
---|---|
EPS (TTM) vs TTM 1 year ago | 48.12 |
More ▼